Navigating the challenges of diagnosing multiple sclerosis
- PMID: 37479366
- DOI: 10.1016/S1474-4422(23)00243-0
Navigating the challenges of diagnosing multiple sclerosis
Conflict of interest statement
I have received research support from the National Institutes of Health, National MS Society, US Department of Defense, Sumaira Foundation, Brainstorm Cell Therapeutics, Bristol Myers Squibb, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis Pharmaceuticals, Octave Bioscience, Roche Genentech, Sanofi Genzyme, and Tiziana Life Sciences. I have also received consulting fees from Banner Life Sciences, Biogen, Bristol Myers Squibb, Janssen, Novartis Pharmaceuticals, Roche Genentech, Sanofi Genzyme, and UCB Biopharma.
Comment on
-
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.Lancet Neurol. 2023 Aug;22(8):750-768. doi: 10.1016/S1474-4422(23)00148-5. Lancet Neurol. 2023. PMID: 37479377 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical